title: Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
abstract: The Drugs for Neglected Diseases initiative (DNDi) is a patients' needs-driven organization committed to the development of new treatments for neglected diseases. Created in 2003, DNDi has delivered four improved treatments for malaria, sleeping sickness and visceral leishmaniasis. A main DNDi challenge is to build a solid R&D portfolio for neglected diseases and to deliver preclinical candidates in a timely manner using an original model based on partnership. To address this challenge DNDi has remodeled its discovery activities from a project-based academic-bound network to a fully integrated process-oriented platform in close collaboration with pharmaceutical companies. This discovery platform relies on dedicated screening capacity and lead-optimization consortia supported by a pragmatic, structured and pharmaceutical-focused compound sourcing strategy.
authors: Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland. jrioset@dndi.org
authors: Jean-Robert
authors: JR
authors: Ioset
authors: Shing
authors: S
authors: Chang
mesh_terms: D055808:Drug Discovery / Q000191:economics / Q000379:methods / Q000458:organization & administration* / Q000639:trends; D004345:Drug Industry; D017146:Models, Organizational; D058069:Neglected Diseases / Q000188:drug therapy*; D016730:Program Development; D055818:Public-Private Sector Partnerships / Q000191:economics / Q000458:organization & administration* / Q000639:trends